News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
101.32
-0.41 (-0.40%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Incyte Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Registration Momentum Builds Across the Oncology Pipeline
February 17, 2026
Issued on behalf of Oncolytics Biotech Inc.
From
USA News Group
Via
GlobeNewswire
Incyte to Present at Upcoming Investor Conferences
February 17, 2026
From
Incyte
Via
Business Wire
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
February 10, 2026
From
Incyte
Via
Business Wire
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results
January 27, 2026
From
Incyte
Via
Business Wire
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
January 05, 2026
From
Incyte
Via
Business Wire
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
December 22, 2025
From
Incyte
Via
Business Wire
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
December 22, 2025
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conference
December 18, 2025
From
Incyte
Via
Business Wire
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
December 17, 2025
From
Incyte
Via
Business Wire
Incyte Announces Change to its Board of Directors
December 12, 2025
From
Incyte
Via
Business Wire
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
December 08, 2025
From
Incyte
Via
Business Wire
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
December 07, 2025
From
Incyte
Via
Business Wire
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
December 07, 2025
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2025
From
Incyte Corporation
Via
Business Wire
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
December 02, 2025
From
Incyte
Via
Business Wire
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
December 01, 2025
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
November 19, 2025
From
Incyte
Via
Business Wire
Incyte’s Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
November 06, 2025
From
Incyte
Via
Business Wire
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
November 04, 2025
From
Prelude Therapeutics, Incorporated
Via
GlobeNewswire
Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
November 03, 2025
From
Incyte
Via
Business Wire
Incyte to Present at Upcoming Investor Conferences
October 30, 2025
From
Incyte
Via
Business Wire
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
October 28, 2025
From
Incyte
Via
Business Wire
Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System
October 27, 2025
From
Incyte and Enable Injections
Via
Business Wire
Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
October 25, 2025
From
Incyte
Via
Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
October 19, 2025
From
Incyte
Via
Business Wire
Data from Incyte’s TGFβR2×PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
October 12, 2025
From
Incyte
Via
Business Wire
Incyte to Report Third Quarter Financial Results
October 08, 2025
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 24, 2025
From
Incyte
Via
Business Wire
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
September 22, 2025
From
Incyte
Via
Business Wire
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
September 18, 2025
From
Incyte
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
